GlaxoSmithKline Confirms Receipt of FDA Letter on Regulatory Reporting

LONDON and PHILADELPHIA, April 08, 2008, 2008 /PRNewswire-FirstCall/ -- GlaxoSmithKline today confirmed it has received a warning letter from the US Food and Drug Administration (FDA) related to reporting requirements for approved medicines. The letter follows a routine FDA inspection of GSK's reporting processes conducted last year.

The observations from the inspection primarily relate to omissions from periodic reports to the FDA regarding Avandia(R) (rosiglitazone maleate), such as the start and progress of clinical trials, and summaries of final data from some clinical trials.

The FDA inspection also reviewed GSK's processes for reporting individual adverse events, which resulted in no inspection citations. The inspection found nothing to suggest that procedures for prompt reporting of adverse events was compromised.

"We take these findings seriously, and corrective steps to make sure we file periodic reports completely and promptly have been taken or are underway," said Dr. Ronald Krall, Chief Medical Officer at GlaxoSmithKline. "These omissions did not interfere with the timely reporting of adverse event information to the FDA."

GSK is committed to taking the appropriate steps to address the concerns raised by the FDA.

After the inspection, GSK initiated a review of applicable processes and reporting systems. The company has made and will continue progress in updating its procedures and improving compliance in this area of reporting, including additional training for employees to ensure that all procedures are followed across all product lines.

The FDA letter acknowledges that information not captured in the periodic reports was, in many cases, submitted to the Agency in other reports and communications. Beyond that, information about the start of clinical trials omitted from some reports was available through posting on clinicaltrials.gov. GSK submitted a corrected 2007 Avandia annual report to the FDA in September 2007, ahead of the FDA's updated final decision on approved labeling for Avandia in November 2007. Clinical trial results are also posted publicly to GSK's clinical trial register.

GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, visit GlaxoSmithKline on the World Wide Web at http://www.gsk.com.

CONTACT: US Media inquiries: Nancy Pekarek, +1-215-751-7709, or Mary AnneRhyne, +1-919-483-2839; or UK Media inquiries: Phil Thomson +(020) 80475502, or Alice Hunt +(020) 8047 5502, or Gwenan White +(020) 8047 5502, orUS Analyst, Investor inquiries: Frank Murdolo, +1-215-751-7002, or TomCurry, +1-215-751-5419, or European Analyst, Investor inquiries: DavidMawdsley +(020) 8047 5564, or Sally Ferguson, +(020) 8047 5543, or GaryDavies, +(020) 8047 5503, all of GlaxoSmithKline

Web site: http://www.gsk.com/http://clinicaltrials.gov/

Company News On-Call: http://www.prnewswire.com/comp/801350.html/

Ticker Symbol: (NYSE:GSK)

Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: April 2008


View comments

Hide
(web1)